SG10201900727QA - Personalized immunotherapy against several neuronal and brain tumors - Google Patents
Personalized immunotherapy against several neuronal and brain tumorsInfo
- Publication number
- SG10201900727QA SG10201900727QA SG10201900727QA SG10201900727QA SG10201900727QA SG 10201900727Q A SG10201900727Q A SG 10201900727QA SG 10201900727Q A SG10201900727Q A SG 10201900727QA SG 10201900727Q A SG10201900727Q A SG 10201900727QA SG 10201900727Q A SG10201900727Q A SG 10201900727QA
- Authority
- SG
- Singapore
- Prior art keywords
- present
- tumor
- relates
- brain tumors
- against several
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 208000014500 neuronal tumor Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000005975 antitumor immune response Effects 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
- C12N9/0032—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with oxygen as acceptor (1.5.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1229—Phosphotransferases with a phosphate group as acceptor (2.7.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
- C12Y105/03—Oxidoreductases acting on the CH-NH group of donors (1.5) with oxygen as acceptor (1.5.3)
- C12Y105/03016—Spermine oxidase (1.5.3.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
- C12Y207/04008—Guanylate kinase (2.7.4.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
Abstract
PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. NO FIGURE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361899680P | 2013-11-04 | 2013-11-04 | |
GBGB1319446.9A GB201319446D0 (en) | 2013-11-04 | 2013-11-04 | Personalized immunotherapy against several neuronal and brain tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201900727QA true SG10201900727QA (en) | 2019-02-27 |
Family
ID=49767624
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201900727QA SG10201900727QA (en) | 2013-11-04 | 2014-11-03 | Personalized immunotherapy against several neuronal and brain tumors |
SG11201603299PA SG11201603299PA (en) | 2013-11-04 | 2014-11-03 | Personalized immunotherapy against several neuronal and brain tumors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603299PA SG11201603299PA (en) | 2013-11-04 | 2014-11-03 | Personalized immunotherapy against several neuronal and brain tumors |
Country Status (27)
Country | Link |
---|---|
US (9) | US10946064B2 (en) |
EP (3) | EP4253401A3 (en) |
JP (2) | JP6632982B2 (en) |
KR (3) | KR102415748B1 (en) |
CN (2) | CN105793280B (en) |
AU (3) | AU2014343599B2 (en) |
BR (1) | BR112016009402A2 (en) |
CA (1) | CA2929445A1 (en) |
CU (1) | CU20160060A7 (en) |
CY (1) | CY1121691T1 (en) |
DK (1) | DK3066115T3 (en) |
EA (1) | EA036517B1 (en) |
ES (1) | ES2733517T3 (en) |
GB (1) | GB201319446D0 (en) |
HR (1) | HRP20191009T1 (en) |
HU (1) | HUE045038T2 (en) |
LT (1) | LT3066115T (en) |
ME (1) | ME03458B (en) |
MX (1) | MX2016005866A (en) |
PL (1) | PL3066115T3 (en) |
PT (1) | PT3066115T (en) |
RS (1) | RS59031B1 (en) |
SG (2) | SG10201900727QA (en) |
SI (1) | SI3066115T1 (en) |
TR (1) | TR201909021T4 (en) |
UA (1) | UA124048C2 (en) |
WO (1) | WO2015063302A2 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
TWI776192B (en) * | 2013-08-05 | 2022-09-01 | 德商伊瑪提克斯生物科技有限公司 | Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same |
MX2019013161A (en) * | 2013-11-04 | 2020-02-03 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors. |
CN105939767B (en) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | Sound electrophoretic apparatus with alliteration electrophoresis chamber |
US10000533B2 (en) | 2014-06-20 | 2018-06-19 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
MX2017013777A (en) * | 2015-04-27 | 2018-03-27 | Cancer Research Tech Ltd | Method for treating cancer. |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
PE20180253A1 (en) * | 2015-06-19 | 2018-02-02 | Immatics Biotechnologies Gmbh | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS TO CREATE SUPPORTS FOR USE AGAINST PANCREAS CANCER AND OTHER TYPES OF CANCER |
MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
CN105092859B (en) * | 2015-08-04 | 2016-09-14 | 中国农业大学 | NET49 albumen is as diabetes biomarker and the application of therapy target |
GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520567D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
US11371099B2 (en) | 2015-11-30 | 2022-06-28 | Mayo Foundation For Medical Education And Research | HEATR1 as a marker for chemoresistance |
GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
IL298653A (en) | 2015-12-11 | 2023-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
US10383896B2 (en) | 2015-12-11 | 2019-08-20 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against various cancers |
CA3008641A1 (en) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
SG10202111399YA (en) | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
GB201604490D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
HRP20221375T1 (en) | 2016-03-16 | 2023-01-06 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
JP7075125B2 (en) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers |
GB201609193D0 (en) * | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
TWI796299B (en) * | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
MA46904A (en) * | 2016-11-23 | 2019-10-02 | Gritstone Oncology Inc | VIRAL ADMINISTRATION OF NEO-ANTIGENS |
DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
KR102639592B1 (en) | 2016-12-08 | 2024-02-21 | 이매틱스 바이오테크놀로지스 게엠베하 | T cell receptors with improved pairing |
TWI796314B (en) * | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
AU2018212584B2 (en) | 2017-01-27 | 2020-12-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
AR110857A1 (en) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER |
CN117224710A (en) | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes |
TW201841937A (en) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | Novel peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
CN112521478A (en) | 2017-04-10 | 2021-03-19 | 伊玛提克斯生物技术有限公司 | Peptides and peptide compositions for immunotherapy of leukemia and other cancers |
CR20190508A (en) * | 2017-04-10 | 2020-01-08 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
TW201841934A (en) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | Novel peptides and combination thereof for use in the immunotherapy against cancers |
CN110612116A (en) | 2017-05-08 | 2019-12-24 | 磨石肿瘤生物技术公司 | Novel alphavirus antigen vector |
US20200393469A1 (en) * | 2017-05-16 | 2020-12-17 | Kurume University | Method for determining eligibility of brain tumor patient for tailor-made type peptide vaccine agent |
CR20210168A (en) | 2017-07-07 | 2021-06-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
WO2019104203A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
US20220153871A1 (en) | 2018-01-04 | 2022-05-19 | Iconic Therapeutics, Inc. | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods |
DE102018107224A1 (en) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers |
CN108623661B (en) * | 2018-05-14 | 2021-04-27 | 中国医学科学院肿瘤医院 | Bispecific polypeptide molecular probe targeting pancreatic cancer tumor cells and application thereof |
TW202016131A (en) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | Peptides for use in immunotherapy against cancers |
DE102018115865A1 (en) * | 2018-06-29 | 2020-02-20 | Immatics Biotechnologies Gmbh | A * 03 restricted peptides for use in cancer immunotherapy and related methods |
US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
TW202024121A (en) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods |
TW202039535A (en) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods |
CN109706065A (en) * | 2018-12-29 | 2019-05-03 | 深圳裕策生物科技有限公司 | Tumor neogenetic antigen load detection device and storage medium |
CN109750040B (en) * | 2019-03-05 | 2023-05-12 | 上海市第七人民医院 | Application of HEATR1 gene or protein inhibitor in preparation of antitumor drugs |
CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US20230204565A1 (en) * | 2020-01-02 | 2023-06-29 | The Regents Of The University Of California | Methods for Culturing Cancer Cells and for Inhibiting Invasion of Cancer |
GR1010022B (en) * | 2020-03-17 | 2021-06-01 | Πανεπιστημιο Πατρων | Methods for determining prognosis of a subject with lung adenocarcinoma and responsiveness to treatment |
AU2021320896A1 (en) | 2020-08-06 | 2023-03-23 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
CN112053785A (en) * | 2020-09-02 | 2020-12-08 | 北京小白世纪网络科技有限公司 | Coronary heart disease diagnosis method and system based on coronary heart disease diagnosis neural network model |
US20230349920A1 (en) * | 2020-09-04 | 2023-11-02 | Meso Scale Technologies, Llc. | Methods for isolating central nervous system surface marker displaying agents |
CN112946279A (en) * | 2021-03-17 | 2021-06-11 | 扬州大学 | Method for detecting serum biomarkers of cervical cancer patient by using sandwich SERS (surface enhanced Raman scattering) immunosensor based on oil-water interface self-assembly |
CN114022472B (en) * | 2021-11-17 | 2022-05-20 | 深圳裕策生物科技有限公司 | Tumor infiltrating lymphocyte analysis method, device and storage medium |
CN114231494B (en) * | 2021-11-29 | 2023-09-05 | 中国科学院动物研究所 | Application and method of USP10 gene and/or Ascl1 gene in inducing fibroblast to transdifferentiate into neuron cell |
CN114146180B (en) * | 2021-12-22 | 2022-12-23 | 首都医科大学附属北京地坛医院 | Application of substance inhibiting CHCHCHD 2 activity in preparation of product for treating NASH and hepatic fibrosis caused by liver injury |
US20230377140A1 (en) * | 2022-02-01 | 2023-11-23 | 4D Path Inc. | Systems and Methods for Image-Based Disease Characterization |
WO2023213904A1 (en) * | 2022-05-04 | 2023-11-09 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | T cell receptor derived binding polypeptides |
EP4382121A1 (en) * | 2022-12-07 | 2024-06-12 | Altevax | Vaccines against ptprz1-positive tumors |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2000E (en) | 1901-04-20 | 1903-11-24 | Albert Lagarde | Folding iron frame for transporting fruit and early vegetables in wagons |
US3119139A (en) | 1961-02-06 | 1964-01-28 | Taylor Mfg | Bottle case inverter |
DE2148469A1 (en) | 1971-09-28 | 1973-04-05 | Ullrich G Messwerkzeug Kg | SPIRIT LEVEL WITH AN ANGLE ADJUSTABLE LEVEL |
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
LU88257I2 (en) | 1978-12-22 | 1994-02-03 | ||
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
NZ266838A (en) | 1993-06-03 | 1997-02-24 | Therapeutic Antibodies Inc | Treatment of patients with anti-tnfalpha antibody, antibody fragment |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
ATE244300T1 (en) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL) |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6514935B1 (en) | 1997-03-14 | 2003-02-04 | President And Fellows Of Harvard | Methods of treating hypertension |
US7030235B1 (en) * | 1998-09-29 | 2006-04-18 | The Brigham & Women's Hospital, Inc. | Compositions to detect lesions associated with hearing loss in the cochlear gene, COCH5B2 |
WO2001057251A2 (en) * | 2000-02-04 | 2001-08-09 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
ATE472601T1 (en) | 2000-03-27 | 2010-07-15 | Technion Res And Dev Of Founda | CLASS I SINGLE-CHAIN MAIN HISTOCOMPATIBILITY COMPLEXES (MHC-I), CODING CONSTRUCTS AND METHODS OF THEIR GENERATION |
CN101712721A (en) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T cell receptor fusions and conjugates and methods of use thereof |
GB0017512D0 (en) * | 2000-07-17 | 2000-08-30 | Smithkline Beecham Biolog | Novel compounds |
EP1383543A4 (en) * | 2001-03-23 | 2006-06-21 | Agy Therapeutics Inc | Use of biomolecular targets in the treatment and visualization of brain tumors |
CA2633171C (en) | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
EP1478772A2 (en) * | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | Mhc-peptide complex binding ligands |
EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
AU2003276403B2 (en) | 2002-11-09 | 2010-04-15 | Adaptimmune Limited | T cell receptor display |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
JP2005245430A (en) | 2003-08-25 | 2005-09-15 | Medeinetto:Kk | Method for inducing ctl |
US7612162B2 (en) | 2004-09-21 | 2009-11-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
CN101160524A (en) | 2005-02-24 | 2008-04-09 | 西米尼斯公司 | Compositions and methods for classifying biological samples |
ES2341295T3 (en) | 2005-09-05 | 2010-06-17 | Immatics Biotechnologies Gmbh | PEPTIDES ASSOCIATED WITH UNITED TUMORS PROMISCUALLY TO MOLECULES OF THE HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II. |
ES2348733T3 (en) | 2006-05-09 | 2010-12-13 | Comacchio International S.A. | DRILLING MACHINE WITH DRILL CHARGER AND CARRUSEL TYPE PROTECTION TUBE. |
HUE026776T2 (en) | 2007-07-27 | 2016-08-29 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
MX2010001086A (en) | 2007-07-27 | 2010-04-09 | Immatics Biotechnologies Gmbh | Novel immunotherapy against neuronal and brain tumors. |
CN101648012A (en) * | 2008-04-24 | 2010-02-17 | 伊玛提克斯生物技术有限公司 | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules for vaccines |
SI2113253T1 (en) | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
PT2119726E (en) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novel and powerful mhc-class ii peptides derived from survivin and neurocan |
EP2172211B1 (en) | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
WO2011051278A1 (en) * | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Lung tumor markers and methods of use thereof |
WO2011051276A1 (en) * | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Colon and rectal tumor markers and methods of use thereof |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
WO2012031122A2 (en) * | 2010-09-03 | 2012-03-08 | Immport Therapeutics, Inc. | Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders |
EP2632955A1 (en) | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
US9103183B2 (en) | 2011-08-03 | 2015-08-11 | Vetco Gray Inc. | Method and apparatus for launching multiple balls in a well |
WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
WO2013071295A2 (en) * | 2011-11-10 | 2013-05-16 | Rutgers, The State University Of New Jersey | Transcript optimized expression enhancement for high-level production of proteins and protein domains |
EP3757134B1 (en) * | 2014-05-28 | 2024-03-06 | NoNO Inc. | Chloride salt of tat-nr2b9c |
DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
-
2013
- 2013-11-04 GB GBGB1319446.9A patent/GB201319446D0/en not_active Ceased
-
2014
- 2014-11-03 EP EP23176827.6A patent/EP4253401A3/en active Pending
- 2014-11-03 BR BR112016009402A patent/BR112016009402A2/en not_active Application Discontinuation
- 2014-11-03 EP EP19166517.3A patent/EP3539979A3/en not_active Withdrawn
- 2014-11-03 ME MEP-2019-193A patent/ME03458B/en unknown
- 2014-11-03 DK DK14792834.5T patent/DK3066115T3/en active
- 2014-11-03 LT LTEP14792834.5T patent/LT3066115T/en unknown
- 2014-11-03 EA EA201690868A patent/EA036517B1/en unknown
- 2014-11-03 EP EP14792834.5A patent/EP3066115B1/en active Active
- 2014-11-03 SG SG10201900727QA patent/SG10201900727QA/en unknown
- 2014-11-03 KR KR1020217016805A patent/KR102415748B1/en active IP Right Grant
- 2014-11-03 SI SI201431228T patent/SI3066115T1/en unknown
- 2014-11-03 CN CN201480059678.5A patent/CN105793280B/en active Active
- 2014-11-03 PT PT14792834T patent/PT3066115T/en unknown
- 2014-11-03 ES ES14792834T patent/ES2733517T3/en active Active
- 2014-11-03 JP JP2016551012A patent/JP6632982B2/en active Active
- 2014-11-03 AU AU2014343599A patent/AU2014343599B2/en active Active
- 2014-11-03 CN CN202010054632.1A patent/CN111303244B/en active Active
- 2014-11-03 KR KR1020227021113A patent/KR102651028B1/en active IP Right Grant
- 2014-11-03 SG SG11201603299PA patent/SG11201603299PA/en unknown
- 2014-11-03 WO PCT/EP2014/073588 patent/WO2015063302A2/en active Application Filing
- 2014-11-03 PL PL14792834T patent/PL3066115T3/en unknown
- 2014-11-03 KR KR1020167014775A patent/KR102414447B1/en active IP Right Grant
- 2014-11-03 UA UAA201604922A patent/UA124048C2/en unknown
- 2014-11-03 TR TR2019/09021T patent/TR201909021T4/en unknown
- 2014-11-03 US US14/531,472 patent/US10946064B2/en active Active
- 2014-11-03 CA CA2929445A patent/CA2929445A1/en active Pending
- 2014-11-03 MX MX2016005866A patent/MX2016005866A/en unknown
- 2014-11-03 RS RS20190775A patent/RS59031B1/en unknown
- 2014-11-03 HU HUE14792834A patent/HUE045038T2/en unknown
-
2016
- 2016-05-04 CU CUP2016000060A patent/CU20160060A7/en unknown
-
2019
- 2019-03-06 AU AU2019201558A patent/AU2019201558B2/en active Active
- 2019-06-04 HR HRP20191009TT patent/HRP20191009T1/en unknown
- 2019-06-27 CY CY20191100670T patent/CY1121691T1/en unknown
-
2020
- 2020-11-19 AU AU2020273312A patent/AU2020273312B2/en active Active
-
2021
- 2021-02-02 US US17/165,638 patent/US11607446B2/en active Active
- 2021-07-30 US US17/390,584 patent/US11890334B2/en active Active
- 2021-07-30 US US17/390,583 patent/US11890333B2/en active Active
- 2021-08-05 JP JP2021129398A patent/JP7426972B2/en active Active
-
2022
- 2022-06-28 US US17/852,206 patent/US11529400B1/en active Active
- 2022-06-28 US US17/852,207 patent/US11529401B2/en active Active
- 2022-06-28 US US17/852,205 patent/US11524059B2/en active Active
- 2022-06-28 US US17/851,417 patent/US11759507B2/en active Active
-
2023
- 2023-03-03 US US18/178,055 patent/US20230263873A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201900727QA (en) | Personalized immunotherapy against several neuronal and brain tumors | |
PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
PH12019502194A1 (en) | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | |
PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
MA39907A (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) | |
WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
MX338294B (en) | Novel immunotherapy against several tumors including neuronal and brain tumors. | |
MX2010001086A (en) | Novel immunotherapy against neuronal and brain tumors. | |
PH12016502008A1 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml) | |
MX2019013161A (en) | Personalized immunotherapy against several neuronal and brain tumors. | |
MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
EA201990696A1 (en) | PERSONALIZED IMMUNOTHERAPY OF SEVERAL SPECIES OF NEURAL TUMORS AND BRAIN TUMORS | |
EA202090816A2 (en) | A NEW METHOD FOR IMMUNOTHERAPY OF SEVERAL TUMORS OF TUMORS SUCH AS LUNG CANCER, INCLUDING NSCLC |